The hepatitis B vaccine is one of the most potent immunizations, usually providing decades of protection against the deadly liver virus. But in about 10% of people it doesn’t work, and in 2020, Amy Huei-Yi Lee, a systems biologist at Simon Fraser University, and her colleagues set out to determine whether they could predict who would benefit. The scientists found that data on recipients’ immune systems such as the abundance of certain proteins and the activity patterns of a few genes foretold whether they would generate defenses against the virus. “We got a sense of what factors drive the vaccine response and what [doesn’t],” Lee says.
Trending
- JAMB commences accreditation of centres for 2025 UTME
- Nigeria, India partner to revolutionize healthcare delivery
- Kebbi partners Indonesia on embryo transfer, artificial insemination
- Accidents: 3,767 killed, 22,373 others injured in Nigeria – FRSC
- COP29: Ghana, 2 others launch roadmap to drive sustainable construction
- COP29 must unlock funds needed for energy transition – ActionAid
- COP29: Advocates push for global shift away from meat overconsumption
- NDLEA thwarts multiple international drug trafficking attempts